showing 1881 abstracts from year 2016
filter abstracts
| Details |
title |
year |
| Details |
GS01 TREATMENT OF HEPATITIS C VIRUS IN PATIENTS WITH ADVANCED CIRRHOSIS: AL... |
2016 |
| Details |
GS02 FIVE-YEAR ON-TREATMENT SYSTEMATICALLY MONITORING OF DYNAMIC CHANGES OF... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
GS03 A GENOME-WIDE ASSOCIATION STUDY IDENTIFIES PNPLA3 AND SLC38A4 AS RISK ... |
2016 |
| Details |
Conclusions:... |
2016 |
| Details |
GS04 THE MULTIKINASE INHIBITOR REGORAFENIB IMPROVES PORTAL HYPERTENSION IN ... |
2016 |
| Details |
GS05 SAF SCORE AS A MARKER FOR MORTALITY IN NAFLD AFTER UP TO 41 YEARS OF F... |
2016 |
| Details |
GS06 A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOP... |
2016 |
| Details |
PS001 PREVALENCE AND CLINICAL IMPORTANCE OF HEPATITIS C VIRUS GENOTYPE 2 K/... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
PS002 C-EDGE HEAD-TO-HEAD: EFFICACY AND SAFETY OF ELBASVIR AND GRAZOPREVIR ... |
2016 |
| Details |
PS003 CYCLOPHILIN INHIBITORS REMODEL THE ENDOPLASMIC RETICULUM OF HCV-INFEC... |
2016 |
| Details |
PS004 THE REAL-WORLD ISRAELI EXPERIENCE OF TREATING CHRONIC HEPATITIS C, GE... |
2016 |
| Details |
PS005 THE EVOLUTION OF PORTAL PRESSURE AFTER VIRAL SUPPRESSION WITH INTERFE... |
2016 |
| Details |
PS006 HCV REINFECTION INCIDENCE AND OUTCOMES AMONG HIV INFECTED MSM IN WEST... |
2016 |
| Details |
PS007 EUROPEAN RA VS DATABASE: FREQUENCY AND CHARACTERISTICS OF RA VS IN TR... |
2016 |
| Details |
Background and Aims:... |
2016 |
| Details |
PS008 HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN ... |
2016 |
| Details |
PS009 THE GUANYLYL CYCLASE STIMULATOR RIOCIGUAT REDUCES LIVER FIBROSIS AND ... |
2016 |
| Details |
PS010 THE EFFECT OF TESTOSTERONE THERAPY ON MUSCLE MASS, BONE MASS AND HAEM... |
2016 |
1 2 3 4 5 6 7 8 ...95 Next